PF-Atlas › Clinical Trials › NCT07179380
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
Treprostinil Palmitil Inhalation Powder · Phase 3
Registry ID
NCT07179380
Phase
Phase 3
Status
Recruiting
Drug / intervention
Treprostinil Palmitil Inhalation Powder
Sponsor
Insmed Incorporated
Start
2026-01-07
Enrollment
344
Locations
145
About this trial
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT07179380 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.